

Supplementary Table 1: The characteristic of AML patients and healthy individuals

Factor	AML-NR	<i>de novo</i> AML	AML-CR	HI
The number of the case	7	27	12	21
Age	66	62	50.5	57
(median; range)	(35-90)	(18-88)	(24-78)	(25-83)
Gender	(5/2)	(14/13)	(5/7)	(11/10)
(Male / Female)				
Clinical index				
WBC (10 ⁹ /L)	4.3	6.0	4.8	6.2
(median; range)	(0.3-29.4)	(1.0-132.7)	(2.1-9.9)	(4.4-8.5)
PLT (10 ⁹ /L)	24.0	40.0	152.3	226.0
(median; range)	(1.0-248.0)	(1.0-632.0)	(12.0-555.0)	(97.0-300.0)
RBC (10 ⁹ /L)	2.3	2.2	3.3	4.9
(median; range)	(1.9-2.8)	(1.1-3.9)	(1.9-4.4)	(4.1-5.9)
Hb (g/L)	59.0	70.0	93.5	145.0
(median; range)	(8.0-71.0)	(48.0-116.0)	(61.0-138.0)	(91.0-165.0)
Blast (%)	80	44	0	/
(median; range)	(29-93)	(21-95)	(0-5)	
FAB classification				
M1	0	1	1	/
M2	0	5	2	/
M3	1	5	5	/
M4	0	2	1	/
M5	4	8	1	/
Undetermined	2	6	2	/
Therapy				/
Chemotherapy	7	27	12	/
Transplantation	0	1	0	/

Notes: WBC: white blood cell, RBC: red blood cell, PLT: platelet, Hb: hemoglobin,

F: female, M: male, CR: complete remission, NR: no remission

Supplementary Table 2: The clinical information of *de novo* AML patients

Case No.	Disease status	Subtype	Genotype	Chemotherapy
P8	<i>de novo</i>	M5	ND	SC
P9	<i>de novo</i>	M2	ND	Azacitidine
P10	<i>de novo</i>	M1	FLT3-ITD, CEBPA	DHA
P11	<i>de novo</i>	M5	DNMT3A, IDH2, SRSF2, RUNX1	MA
P12	<i>de novo</i>	M3	ND	Refused therapy
P13	<i>de novo</i>	M2b	AML1-ETO	SC
P14	<i>de novo</i>	M3	FLT3-ITD, PML-RAR α	ATRA+ATO
P15	<i>de novo</i>	M2	K-RAS, DEK-CAN, EA2-HLF	DCAG
P16	<i>de novo</i>	Undetermined	AML1-ETO, TET2, RUNX1-RUNX1T1	IA
P17	<i>de novo</i>	M2	MLL-ELL	DA
P18	<i>de novo</i>	M3	PML-RAR α	ATRA+ATO
P19	<i>de novo</i>	Undetermined	TP53	DCAG
P20	<i>de novo</i>	M5	MLL-AF9, EVI1	IA
P21	<i>de novo</i>	M4	ND	IDA+ Azacitidine
P22	<i>de novo</i>	M3	PML-RAR α	ATRA+ATO
P23	<i>de novo</i>	M5	FLT3-ITD, CEBPA	IA
P24	<i>de novo</i>	M5	ATM, JAK2, CXCR4	Ara-C+DCA
P25	<i>de novo</i>	M5	FLT3	IA
P26	<i>de novo</i>	Undetermined	ND	IA
P27	<i>de novo</i>	Undetermined	NPM1	DA
P28	<i>de novo</i>	Undetermined	ND	Refused therapy
P29	<i>de novo</i>	Undetermined	NRAS, TP53, STAG2	IA
P30	<i>de novo</i>	M5	ND	SC
P31	<i>de novo</i>	M4	TET2, SF3B1	DCAG
P32	<i>de novo</i>	M2	ND	DA
P33	<i>de novo</i>	M3	PML-RAR α	ATRA+ATO
P34	<i>de novo</i>	M5	ND	IA

Notes: ND: not detected; DHA: daunorubicin+ homoharringtonine + cytarabine; MA: mitoxantrone+ cytarabine; SC: supportive care; ATRA: all-trans-retinoic acid; ATO: arsenic trioxide; DA: daunorubicin+ cytarabine; DCAG: decitabine+ aclarubicin + cytarabine+ recombinant granulocyte colony-stimulating factor; IA: idarubicin+ cytarabine; IDA: idarubicin; DCA: Decitabine; Ara-C: cytarabine